MS Pharma
Address: 7th Circle- Zahran Plaza Bldg., P.O Box 142904, Amman, 11844About Us
MS Pharma is a leading pharmaceutical, healthcare solutions provider and partner of choice company that is manufacturing and marketing generic medicines through its leading affiliates in several strategic markets across the MENA region. The company is headquartered in Jordan, It unifies EL KENDI in Algeria, UPM in Jordan, MS Pharma Injectables and MS Pharma Turkey. . MS Pharma is committed to offer high quality generic medicines with added value by basing its production on new technologies and state-of-the-art facilities implemented all around the MENA region. MS Pharma is also one of the first-movers towards new generation biotech and biosimilars in which the company has acquired a considerable expertise and know-how across the region. MS Pharma aims to grow into the leading generic pharmaceutical and healthcare company in MENA region by targeting strategic therapeutic classes and formulations with higher entry barriers. Today, we employ 2140 employee and are present in 20 countries.
Sectors
- Generic Formulations
- Contract Manufacturing
- Contract Research & Development
Categories
- Finished Dosage
- Generic Formulations
- Biosimilars
- Biotechnology
- BioPharmaceuticals
- Licensing
- Injectables
- Parenterals
News
MS Pharma Group Signs Exclusive Biosimilars Partnership Agreement with Hetero
Algiers, Algeria / Amman, Jordan —MS Pharma Group, a leading regional pharmaceutical company in the MENA region, has signed a strategic partnership agreement with Hetero Group, a global pharmaceutical company, to localize five established biosimilars across key therapeutic areas, including oncology, immunology and hematology.
MS Pharma becomes Partner for the Commercialization of FYB202 / ustekinumab in the MENA Region
MS Pharma is a leading regional pharmaceutical company in the MENA region and specializes in the distribution of biotechnological as well as generic drugs. The company will have rights to license, commercialize and produce FYB202 locally at its new Biosimilars site in Saudi Arabia for the Gulf Cooperation Council (GCC) countries as well as further countries of the MENA region. In February 2023, Formycon entered into a license agreement with Fresenius Kabi for the commercialization of FYB202 in key global markets. As part of this agreement, Formycon retained the rights to separately out-license FYB202 for commercialization in specific countries of the MENA region.
MS Pharma Announces Acquisition of Genepharm
MS Pharma, a fast growing pharmaceutical company based in Jordan and operating across the Middle East, Turkey and Africa, announced today that it has entered into an agreement to acquire 100% of the outstanding shares in Genepharm, a leading European pharmaceutical company. Genepharm’s senior management will remain with the business and help guide the company through the next phase of its growth. The transaction is expected to close by the end of April.
Source: The Partnership Tree | https://www.pharmaservicesdirectory.com